Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 1Phase 3 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Squamous Cell Carcinoma of Head and Neck 1Sjogren's Syndrome 1Scleroderma, Systemic 1Psoriasis 1Multiple Sclerosis 1Melanoma 1Lupus Erythematosus, Systemic 1Lung Neoplasms 1Inflammatory Bowel Diseases 1Hematologic Neoplasms 1Dermatomyositis 1Crohn Disease 1Colitis, Ulcerative 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Autoimmune Diseases 1Arthritis, Rheumatoid 1Arthritis, Psoriatic 1

Interventions

Radiotherapy 38Carboplatin 37pembrolizumab 36Cisplatin 34Paclitaxel 26Pemetrexed 24Docetaxel 18Nivolumab 17Gemcitabine 17Bevacizumab 17Specimen Handling 16Magnetic Resonance Spectroscopy 16Cyclophosphamide 15osimertinib 14Irinotecan 13Etoposide 13Radiation 12Erlotinib Hydrochloride 12durvalumab 11Topotecan 10Cetuximab 10Radiosurgery 8Immunoglobulin G 8Fluorouracil 8Everolimus 8Disulfides 8Celecoxib 8fludarabine 7Taxes 7Ipilimumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lung Neoplasms × Platinum Compounds × Clear all
NCT05358691 2025-04-16

A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants

Rutgers, The State University of New Jersey

Phase 1 Withdrawn
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡